Welcome to the Newsroom
20 January 2017
Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the
“Company”) today announced the first patient has been dosed as part of the enlarged
randomised phase of its AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer.
Article as pdf